Crown Bioscience Showcasing New Models and Services at the 76th American Diabetes Association Meeting
SANTA CLARA, California, June 2, 2016 /PRNewswire/ -- Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, will showcase new models and services during the 76th American Diabetes Association's (ADA) meeting.
Logo - http://photos.prnewswire.com/prnh/20160405/351602LOGO
CrownBio will exhibit its new cardiovascular, renal and metabolic disease models, which include the most amenable models available for translational research in the field, at booth 1601 at ADA June 10-14 in New Orleans.
"With the acquisition of PreClinOmics earlier this year, CrownBio has created a center of excellence in global translational drug development specifically for cardiovascular and metabolic disease," said Jim Wang, M.D., senior vice president of cardiovascular and metabolic disease at CrownBio.
The authors of four CrownBio scientific posters will be presenting their data at 12 p.m. June 12 (posters 79, 308 and 911) and at 12 p.m. June 13 (poster 1822). Additionally, CrownBio's research poster on the effects of anesthesia on insulin release (poster 2546) has been selected for publication in the June 2016 supplement to the journal Diabetes®.
"We see this as an opportunity to speak to CVMD thought leaders to discuss the latest breakthroughs in the clinic," said Laurie Heilmann, senior vice president of global strategy, marketing and business development. "With obesity and diabetes becoming pandemic, there is an urgent need to find better models that mirror all aspects of human disease, including late-stage complications such as diabetic nephropathy and heart disease."
CrownBio has long been at the forefront of CVMD research and is now providing an expanded range of solutions to the pharmaceutical industry including: discovery services, analytical services, ADME/PK services and safety/non-GLP toxicology services, alongside a unique collection of genetic models.
CrownBio works with clients in the pharmaceutical industry from large corporations to virtual startups and is committed to better clinical outcomes and lowering the cost of drug development.
For more information on ADA and CrownBio's commitment to furthering the field of CVMD research, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
Share this article